International Stem Cell Corporation
ISCO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.05 | 0.06 | 0.05 |
| FCF Yield | -23.51% | 170.47% | 22.28% | -36.45% |
| EV / EBITDA | 22.96 | 15.28 | 226.08 | -34.47 |
| Quality | ||||
| ROIC | -1.62% | -15.45% | -4.83% | -50.77% |
| Gross Margin | 58.57% | 59.16% | 60.04% | 59.10% |
| Cash Conversion Ratio | -0.06 | -7.09 | -1.00 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.56% | 2.77% | 4.70% | -8.84% |
| Free Cash Flow Growth | -118.09% | 163.55% | 123.92% | -198.89% |
| Safety | ||||
| Net Debt / EBITDA | 18.38 | 12.82 | 160.59 | -17.73 |
| Interest Coverage | -0.47 | -4.77 | -1.45 | -15.01 |
| Efficiency | ||||
| Inventory Turnover | 3.28 | 2.52 | 2.36 | 2.48 |
| Cash Conversion Cycle | 135.89 | 130.05 | 151.91 | 127.00 |